ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement

S. Green; S. Tuck; J. Long; T. Green; A. Green; P. Ellis; A. Haire; C. Moss; F. Cahill; N. McCartan; L. Brown; A. Santaolalla; T. Marsden; M. Rodriquez Justo; J. Hadley; S. Punwani; G. Attard; H. Ahmed; C. M. Moore; M. Emberton; M. Van Hemelrijck

doi:10.1186/s40900-021-00322-w

ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement

S. Green, S. Tuck, J. Long, T. Green, A. Green, P. Ellis, A. Haire, C. Moss, F. Cahill, N. McCartan, L. Brown, A. Santaolalla, T. Marsden, M. Rodriquez Justo, J. Hadley, S. Punwani, G. Attard, H. Ahmed, C. M. Moore, M. EmbertonM. Van Hemelrijck^*

^*Corresponding author for this work

Comprehensive Cancer Centre

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Abstract

Background: ReIMAGINE aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (PCa) and develop a new image-based method (with biomarkers) for diagnosing high/low risk PCa in men. ReIMAGINE’s varied patient and public involvement (PPI) and engagement (PE) strategy maximises the impact of its scientific output by informing and shaping the different stages of research. Aims: Through including the voice of patients and the public, the ReIMAGINE Consortium aims to translate these different perspectives into the design and implementation process. This will improve the overall quality of the research by:reflecting the needs and priorities of patients and the public, ensuring methods and procedures are feasible and appropriateensuring information is relevant and accessible to those being recruited to the studyidentifying dissemination channels relevant to patients/the public and developing outputs that are accessible to a lay audience With support from our patient/user groups, the ReIMAGINE Consortium aims to improve our ability to derive prognostic information and allocate men to the most appropriate and effective therapies, using a novel image-based risk stratification with investigation of non-imaging biomarkers. Findings: We have been working with patients and the public from initiation of the project to ensure that the research is relevant to men and their families. Our PPI Sub-Committee, led by a PCa patient, has been involved in our dissemination strategy, outreach activities, and study design recommendations. For example, the sub-committee have developed a variety of informative videos relevant and accessible to those being recruited, and organised multiple online research engagement events that are accessible to a lay audience. As quoted by one of the study participants, “the more we present the benefits and opportunities to patients and the public, the more research commitment we obtain, and the sooner critical clinical questions such as PCa diagnostics will be addressed”.

Original language	English
Article number	81
Journal	Research involvement and engagement
Volume	7
Issue number	1
Early online date	17 Nov 2021
DOIs	https://doi.org/10.1186/s40900-021-00322-w
Publication status	Published - Dec 2021

Keywords

Cancer
Patient and public engagement
Patient and public involvement
Prostate cancer
Study design

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40900-021-00322-w

Cite this

Green, S., Tuck, S., Long, J., Green, T., Green, A., Ellis, P., Haire, A., Moss, C., Cahill, F., McCartan, N., Brown, L., Santaolalla, A., Marsden, T., Justo, M. R., Hadley, J., Punwani, S., Attard, G., Ahmed, H., Moore, C. M., ... Van Hemelrijck, M. (2021). ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement. Research involvement and engagement, 7(1), Article 81. https://doi.org/10.1186/s40900-021-00322-w

@article{4fc1718a82554c2e85ab0a7cc119f29f,

title = "ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement",

abstract = "Background: ReIMAGINE aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (PCa) and develop a new image-based method (with biomarkers) for diagnosing high/low risk PCa in men. ReIMAGINE{\textquoteright}s varied patient and public involvement (PPI) and engagement (PE) strategy maximises the impact of its scientific output by informing and shaping the different stages of research. Aims: Through including the voice of patients and the public, the ReIMAGINE Consortium aims to translate these different perspectives into the design and implementation process. This will improve the overall quality of the research by:reflecting the needs and priorities of patients and the public, ensuring methods and procedures are feasible and appropriateensuring information is relevant and accessible to those being recruited to the studyidentifying dissemination channels relevant to patients/the public and developing outputs that are accessible to a lay audience With support from our patient/user groups, the ReIMAGINE Consortium aims to improve our ability to derive prognostic information and allocate men to the most appropriate and effective therapies, using a novel image-based risk stratification with investigation of non-imaging biomarkers. Findings: We have been working with patients and the public from initiation of the project to ensure that the research is relevant to men and their families. Our PPI Sub-Committee, led by a PCa patient, has been involved in our dissemination strategy, outreach activities, and study design recommendations. For example, the sub-committee have developed a variety of informative videos relevant and accessible to those being recruited, and organised multiple online research engagement events that are accessible to a lay audience. As quoted by one of the study participants, “the more we present the benefits and opportunities to patients and the public, the more research commitment we obtain, and the sooner critical clinical questions such as PCa diagnostics will be addressed”.",

keywords = "Cancer, Patient and public engagement, Patient and public involvement, Prostate cancer, Study design",

author = "S. Green and S. Tuck and J. Long and T. Green and A. Green and P. Ellis and A. Haire and C. Moss and F. Cahill and N. McCartan and L. Brown and A. Santaolalla and T. Marsden and Justo, {M. Rodriquez} and J. Hadley and S. Punwani and G. Attard and H. Ahmed and Moore, {C. M.} and M. Emberton and {Van Hemelrijck}, M.",

note = "Funding Information: ReIMAGINE Screening is funded by The Medical Research Council, U.K. (MRC), grant number MR/R014043/1 and Cancer Research U.K. (CRUK). Funding Information: Caroline M Moore receives funding from Prostate Cancer UK, Movember, the Medical Research Council, Cancer Research UK and the NIHR. Mark Emberton receives research support from the United Kingdom{\textquoteright}s National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre. Shonit Punwani receives research support from the United Kingdom{\textquoteright}s National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre. Mieke Van Hemelrijck receives funding from Cancer Research UK. Katharina Beyer kindly supported the revisions of the manuscript. We would also like to thank all the members of the ReIMAGINE Consortium for their time and support: Coolen T, Tuck S, Corbett G, Wingate A, Akbar F, Pervez H, Thakali S, Henderson A, Tekin D, Brembilla G, Gong F, Giganti F, Rawlins F, Tam H, Bholastewart H, Keskin S, Bertoncelli M, Maynard W, Bevan C, Boutros P, Feber A, Whitaker H, Freeman A, Domany E, Mason M, Padhani A, Aboagye E, Kaplan R, Parker C, Parker P, Sidhu H, Kopcke D, Isaac E, Beeston T, Clement J, Soteriou K. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s40900-021-00322-w",

language = "English",

volume = "7",

journal = "Research involvement and engagement",

issn = "2056-7529",

publisher = "BioMed Central Ltd.",

number = "1",

}

Green, S, Tuck, S, Long, J, Green, T, Green, A, Ellis, P, Haire, A, Moss, C, Cahill, F, McCartan, N, Brown, L, Santaolalla, A, Marsden, T, Justo, MR, Hadley, J, Punwani, S, Attard, G, Ahmed, H, Moore, CM, Emberton, M & Van Hemelrijck, M 2021, 'ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement', Research involvement and engagement, vol. 7, no. 1, 81. https://doi.org/10.1186/s40900-021-00322-w

TY - JOUR

T1 - ReIMAGINE

T2 - a prostate cancer research consortium with added value through its patient and public involvement and engagement

AU - Green, S.

AU - Tuck, S.

AU - Long, J.

AU - Green, T.

AU - Green, A.

AU - Ellis, P.

AU - Haire, A.

AU - Moss, C.

AU - Cahill, F.

AU - McCartan, N.

AU - Brown, L.

AU - Santaolalla, A.

AU - Marsden, T.

AU - Justo, M. Rodriquez

AU - Hadley, J.

AU - Punwani, S.

AU - Attard, G.

AU - Ahmed, H.

AU - Moore, C. M.

AU - Emberton, M.

AU - Van Hemelrijck, M.

N1 - Funding Information: ReIMAGINE Screening is funded by The Medical Research Council, U.K. (MRC), grant number MR/R014043/1 and Cancer Research U.K. (CRUK). Funding Information: Caroline M Moore receives funding from Prostate Cancer UK, Movember, the Medical Research Council, Cancer Research UK and the NIHR. Mark Emberton receives research support from the United Kingdom’s National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre. Shonit Punwani receives research support from the United Kingdom’s National Institute of Health Research (NIHR) UCLH/UCL Biomedical Research Centre. Mieke Van Hemelrijck receives funding from Cancer Research UK. Katharina Beyer kindly supported the revisions of the manuscript. We would also like to thank all the members of the ReIMAGINE Consortium for their time and support: Coolen T, Tuck S, Corbett G, Wingate A, Akbar F, Pervez H, Thakali S, Henderson A, Tekin D, Brembilla G, Gong F, Giganti F, Rawlins F, Tam H, Bholastewart H, Keskin S, Bertoncelli M, Maynard W, Bevan C, Boutros P, Feber A, Whitaker H, Freeman A, Domany E, Mason M, Padhani A, Aboagye E, Kaplan R, Parker C, Parker P, Sidhu H, Kopcke D, Isaac E, Beeston T, Clement J, Soteriou K. Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Background: ReIMAGINE aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (PCa) and develop a new image-based method (with biomarkers) for diagnosing high/low risk PCa in men. ReIMAGINE’s varied patient and public involvement (PPI) and engagement (PE) strategy maximises the impact of its scientific output by informing and shaping the different stages of research. Aims: Through including the voice of patients and the public, the ReIMAGINE Consortium aims to translate these different perspectives into the design and implementation process. This will improve the overall quality of the research by:reflecting the needs and priorities of patients and the public, ensuring methods and procedures are feasible and appropriateensuring information is relevant and accessible to those being recruited to the studyidentifying dissemination channels relevant to patients/the public and developing outputs that are accessible to a lay audience With support from our patient/user groups, the ReIMAGINE Consortium aims to improve our ability to derive prognostic information and allocate men to the most appropriate and effective therapies, using a novel image-based risk stratification with investigation of non-imaging biomarkers. Findings: We have been working with patients and the public from initiation of the project to ensure that the research is relevant to men and their families. Our PPI Sub-Committee, led by a PCa patient, has been involved in our dissemination strategy, outreach activities, and study design recommendations. For example, the sub-committee have developed a variety of informative videos relevant and accessible to those being recruited, and organised multiple online research engagement events that are accessible to a lay audience. As quoted by one of the study participants, “the more we present the benefits and opportunities to patients and the public, the more research commitment we obtain, and the sooner critical clinical questions such as PCa diagnostics will be addressed”.

AB - Background: ReIMAGINE aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (PCa) and develop a new image-based method (with biomarkers) for diagnosing high/low risk PCa in men. ReIMAGINE’s varied patient and public involvement (PPI) and engagement (PE) strategy maximises the impact of its scientific output by informing and shaping the different stages of research. Aims: Through including the voice of patients and the public, the ReIMAGINE Consortium aims to translate these different perspectives into the design and implementation process. This will improve the overall quality of the research by:reflecting the needs and priorities of patients and the public, ensuring methods and procedures are feasible and appropriateensuring information is relevant and accessible to those being recruited to the studyidentifying dissemination channels relevant to patients/the public and developing outputs that are accessible to a lay audience With support from our patient/user groups, the ReIMAGINE Consortium aims to improve our ability to derive prognostic information and allocate men to the most appropriate and effective therapies, using a novel image-based risk stratification with investigation of non-imaging biomarkers. Findings: We have been working with patients and the public from initiation of the project to ensure that the research is relevant to men and their families. Our PPI Sub-Committee, led by a PCa patient, has been involved in our dissemination strategy, outreach activities, and study design recommendations. For example, the sub-committee have developed a variety of informative videos relevant and accessible to those being recruited, and organised multiple online research engagement events that are accessible to a lay audience. As quoted by one of the study participants, “the more we present the benefits and opportunities to patients and the public, the more research commitment we obtain, and the sooner critical clinical questions such as PCa diagnostics will be addressed”.

KW - Cancer

KW - Patient and public engagement

KW - Patient and public involvement

KW - Prostate cancer

KW - Study design

UR - http://www.scopus.com/inward/record.url?scp=85119254627&partnerID=8YFLogxK

U2 - 10.1186/s40900-021-00322-w

DO - 10.1186/s40900-021-00322-w

M3 - Letter

AN - SCOPUS:85119254627

SN - 2056-7529

VL - 7

JO - Research involvement and engagement

JF - Research involvement and engagement

IS - 1

M1 - 81

ER -

ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this